艾塞那肽联合多烯磷脂酰胆碱对酒精性脂肪肝患者 血清HMGB1、APN水平的影响.

Objective To analyze the effect of exenatide combined with polyene phosphatidyl choline on alcoholic fatty liver disease and their effect on serum high mobility group protein B1（HMGB1）and adiponectin （APN）levels. Methods A total of 108 patients with alcoholic fatty liver disease admitted to our hospital from January 2020 to January 2022 were divided into observation group and control group by random number table method, with 54 cases in each group. The control group was treated with polyene phosphatidyl choline, and the observation group was treated with exenatide on the basis of control group. The therapeutic effect and serum levels of HMGB1 and APN in 2 groups were observed and compared between the two groups. Results After 3 months of treatment, the clinical symptoms of both groups were significantly improved and the clinical symptoms disappeared faster. The total clinical effective rate of the observation group was significantly higher than that of the control group （96.30% vs. 83.33%, P<0.05）. There were no significant differences in the serum ALT, AST, TC, TG and TBil between the two groups before treatment（all P>0.05）. After treatment, the all indexes of the two groups were significantly decreased, and those of the observation group were lower than of the control group（P<0.01）. There was no significant difference in the serum HMGB1 and APN levels between the two groups before treatment. After treatment, the serum HMGB1 level in the two groups was significantly decreased（P<0.001）, and the serum HMGB1 level in the observation group was lower than that in the control group（P<0.05）. After treatment, the serum APN levels of both groups were significantly increased（P<0.001）, and the level of observation group was significantly higher than of the control group（P<0.05）. There was no significant difference in the adverse reactions between the two groups（P>0.05）. Conclusion Exenatide combined with polyene phosphatidyl choline can improve the therapeutic effect of alcoholic fatty liver disease, reduce serum HMGB1 level and increase serum APN level safely. [ABSTRACT FROM AUTHOR]